微生物群
失调
医学
人体微生物群
疾病
人类微生物组计划
人类健康
噬菌体疗法
计算生物学
风险分析(工程)
生物信息学
生物技术
生物
病理
环境卫生
大肠杆菌
噬菌体
基因
生物化学
作者
Monika Yadav,Nar Singh Chauhan
出处
期刊:
日期:2021-11-10
卷期号:10: goab046-goab046
被引量:148
标识
DOI:10.1093/gastro/goab046
摘要
Human gut-microbiome explorations have enriched our understanding of microbial colonization, maturation, and dysbiosis in health-and-disease subsets. The enormous metabolic potential of gut microbes and their role in the maintenance of human health is emerging, with new avenues to use them as therapeutic agents to overcome human disorders. Microbiome therapeutics are aimed at engineering the gut microbiome using additive, subtractive, or modulatory therapy with an application of native or engineered microbes, antibiotics, bacteriophages, and bacteriocins. This approach could overcome the limitation of conventional therapeutics by providing personalized, harmonized, reliable, and sustainable treatment. Its huge economic potential has been shown in the global therapeutics market. Despite the therapeutic and economical potential, microbiome therapeutics is still in the developing stage and is facing various technical and administrative issues that require research attention. This review aims to address the current knowledge and landscape of microbiome therapeutics, provides an overview of existing health-and-disease applications, and discusses the potential future directions of microbiome modulations.
科研通智能强力驱动
Strongly Powered by AbleSci AI